Latest News

agitation
Potential Label Expansion for Igalmi: Pre-Supplemental New Drug Application Meeting Package Submitted

July 21st 2025

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

schizophrenia cancer risk screening
Long-Term Antipsychotic Use May Be Linked to Increased Breast Cancer Risk in Women With Schizophrenia

July 18th 2025

Dee/Adobe Stock
Toward a Muscarinic Agent Solution for the Presynaptic Dopamine Problem in Schizophrenia

July 12th 2025

schizophrenia
Spotlight on Schizophrenia Data: Insights From Recent Conferences

July 11th 2025

schizophrenia
sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia

July 8th 2025

Video Series
Video Interviews
Podcasts
schizophrenia evolution psychiatry
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.